IHT Wealth Management’s ImmunityBio IBRX Stock Holding History

IHT Wealth Management’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-14,826	Closed	-$114K	–	1305
2026 Q1	$114K	Buy	14,826 +4,716	+47%	+$32.3K	﹤0.01%	1218
2025 Q4	$20K	Buy	+10,110	New	+$22.9K	﹤0.01%	1174

Other funds holding IBRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

IHT Wealth Management's IBRX Position: Q2 2026 in Review

IHT Wealth Management sold out of ImmunityBio (IBRX) in Q2 2026, closing a stake of 14,826 shares — an estimated $114K sold.

IHT Wealth Management first reported a position in IBRX in Q4 2025 and held it in 2 quarters. The position peaked at $114K in Q1 2026. 404 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

IHT Wealth Management reported no remaining ImmunityBio position as of Q2 2026 after selling out during the quarter.
IHT Wealth Management sold 14,826 ImmunityBio shares in Q2 2026, an estimated $114K.
IHT Wealth Management first reported a position in ImmunityBio in Q4 2025 and held it in 2 quarters.
IHT Wealth Management's ImmunityBio position peaked at $114K in Q1 2026.
404 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on IHT Wealth Management's 13F filing for Q2 2026, filed 14 Aug 2026.